tamoxifen and glp-1 Receptor Agonists in Breast Cancer: 5 Key Clinical Takeaways GLP-1 Agonists Poised to Impact

[DOI] [PubMed] [Google Scholar] 143.Wadden TA, Chao AM, Machineni S, Kushner R, Ard J, et al

In a recently published phase 2 clinical trial, participants lost up to 24.2% body weight at 48 weeks on the 12 mg dose (Jastreboff et al., 2023)

Following two months of treatment, volunteers were once again offered their favorite beverage for two hours, as before

Close coordination between your gastroenterologist and prescribing physician is essential to monitor for symptom changes and distinguish medication side effects from disease flares

Retatrutide Blood Tests & Monitoring Retatrutide is a GLP-1/GIP/glucagon receptor agonist research compound

4 Primary Uses Adults with low IGF-1 levels, reduced lean body mass, or chronic fatigue